135 related articles for article (PubMed ID: 8063621)
1. Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
Miyauchi S; Imaoka T; Utsunomiya T; Hayashi K; Kubo M; Kawaguchi T; Matsui Y
Jpn J Cancer Res; 1994 Jun; 85(6):665-8. PubMed ID: 8063621
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Fujii S; Fukushima M; Shimamoto Y; Ohshimo H; Imaoka T; Shirasaka T
Jpn J Cancer Res; 1989 Feb; 80(2):173-81. PubMed ID: 2498252
[TBL] [Abstract][Full Text] [Related]
3. [Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].
Shirasaka T; Fukushima M; Shimamoto Y; Kimura Y; Ohshimo H; Imaoka T; Kimura A; Utsunomiya T; Fujii S
Gan To Kagaku Ryoho; 1990 May; 17(5):1051-8. PubMed ID: 2334171
[TBL] [Abstract][Full Text] [Related]
4. Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
Miyauchi S; Imaoka T; Okada T; Motoyama M; Kawaguchi T; Akiyama H; Odomi M
Jpn J Pharmacol; 1996 Feb; 70(2):139-48. PubMed ID: 8866751
[TBL] [Abstract][Full Text] [Related]
5. [BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
Fujii S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2244-50. PubMed ID: 2955745
[TBL] [Abstract][Full Text] [Related]
6. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
[TBL] [Abstract][Full Text] [Related]
7. [Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Fujita F; Fujita M; Inaba H; Taguchi T
Gan To Kagaku Ryoho; 1993 Feb; 20(2):223-8. PubMed ID: 8434959
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Ogata Y; Akagi Y; Nozoe Y; Sasatomi T; Miyagi Y; Nakagawa M; Matono K; Kobayashi H; Shirouzu K
Gan To Kagaku Ryoho; 2001 May; 28(5):655-60. PubMed ID: 11383214
[TBL] [Abstract][Full Text] [Related]
9. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
10. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
12. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
13. Mutagenic and clastogenic properties of (3-[3-(6-benzoyloxy-3-cyano-2- pyridyloxycarbonyl) benzoyl]-1-ethoxymethyl-5-fluorouracil) (BOF-A2), a new 5-fluorouracil derivative with anti-tumour activity.
Shibahara T; Kaneko E; Itoh T; Awogi T; Tsushimoto G; Takahashi N; Marshall RR; Kirkland DJ
J Toxicol Sci; 1993 Aug; 18 Suppl 3():11-9. PubMed ID: 8258847
[TBL] [Abstract][Full Text] [Related]
14. [Experimental and clinical study of interactions between fluorinated pyrimidine derivatives and anticoagulants].
Ogawa J; Inoue H; Koide S; Kawada S; Shohtsu A
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2265-71. PubMed ID: 3136697
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice].
Shirasaka T; Fujita F; Fujita M; Fukushima M; Taguchi T; Fujii S
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1871-6. PubMed ID: 2393305
[TBL] [Abstract][Full Text] [Related]
16. [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
Suenaga M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3313-8. PubMed ID: 2825604
[TBL] [Abstract][Full Text] [Related]
17. [Antineoplastic effect of UFT therapy (uracil-FT-207 combination therapy) on experimental pancreatic cancer transplanted in the pancreas and subcutaneous region].
Ohyama K; Koike D; Odake Y; Takiyama Y; Saitoh T; Kagaya T; Takebe T; Ishii K
Gan To Kagaku Ryoho; 1982 Dec; 9(12):2168-74. PubMed ID: 6307180
[TBL] [Abstract][Full Text] [Related]
18. Effect of uracil on metabolism of 5-fluorouracil in vitro.
Ikenaka K; Shirasaka T; Kitano S; Fujii S
Gan; 1979 Jun; 70(3):353-9. PubMed ID: 467897
[TBL] [Abstract][Full Text] [Related]
19. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.
Fujii S; Fukushima M; Shimamoto Y; Shirasaka T
Jpn J Cancer Res; 1989 Jun; 80(6):509-12. PubMed ID: 2503471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
